A Featured Acibadem Review Route
Acibadem publishes a group-level CAR-T pathway and identifies a Cell Therapy Unit at Altunizade Hospital. This campaign uses Acibadem Altunizade as its featured partner review route; the specialist team must still confirm the appropriate campus, indication and current availability for each patient.
Acibadem is not the patient’s only option. MedTransplant can also help request comparison with other suitable verified programs.
CAR-T Is for Selected Cases
CAR-T cell therapy is considered only for selected relapsed or refractory hematologic malignancies after specialist review. A diagnosis of leukemia, lymphoma or multiple myeloma does not by itself establish eligibility.
Relapsed means a cancer has returned after response; refractory means it has not responded adequately. Even in these settings, another therapy may be safer, more appropriate or more immediately available.
What the Specialist Team Must Confirm
The exact indication, target, product and campus availability must be confirmed for the individual case. Publication of this pathway does not promise eligibility, manufacturing access, timing, price or outcome.
- Exact diagnosis, subtype and disease target
- Prior treatment lines and documented response
- Current disease burden and clinical stability
- Organ function, infection risk and performance status
- Alternative therapies and treatment sequencing
- Whether cell collection and manufacturing are feasible
A Multi-Step Cellular-Therapy Process
A possible pathway may include records review, confirmatory testing, leukapheresis, laboratory modification and manufacturing, bridging treatment where appropriate, lymphodepleting treatment, cell infusion and close observation. The sequence can change or stop after specialist reassessment.
Specialist Monitoring Is Essential
CAR-T can cause cytokine release syndrome, neurologic toxicity, infection, prolonged low blood counts and later immune complications. The treating program must explain its monitoring and emergency-response plan as well as long-term follow-up.
Records for Preliminary Review
A complete, dated record set helps specialists decide whether further review is reasonable before travel.
- Current hematology or oncology summary
- Pathology, immunophenotyping and molecular results
- Complete treatment timeline and response assessments
- Recent imaging, marrow or disease-status reports
- Blood counts, organ-function and infection results
- Current medicines and active complications
Travel Only After Meaningful Feedback
International travel should be planned only after the team has reviewed the available information and explained the next clinical step. A patient who is acutely unwell should seek local urgent care rather than wait for travel arrangements.
Compare Suitable Verified Programs
Program comparison should consider clinical fit, target and product pathway, capacity, monitoring, continuity and the patient’s ability to travel safely—not promotional claims or unsupported rankings.
No Unsupported Price or Outcome Claims
MedTransplant does not publish a guaranteed price, response rate or treatment slot. Any hospital estimate remains conditional on the clinical plan, cell pathway, admission, complications and follow-up needs.
Plan Care After Returning Home
The treating program and the patient’s local hematology team should define responsibilities for blood counts, infection prevention, immune recovery, response assessment, late effects and urgent communication.
Preparation by country
International CAR-T pathways
Prepare a case-specific specialist review before travel from four campaign countries.
Frequently Asked Questions
Who may be considered for CAR-T cell therapy?
Only selected patients with particular relapsed or refractory hematologic malignancies may be considered after specialist review of the exact diagnosis, target, prior treatments, disease status and overall health.
Does a leukemia, lymphoma or myeloma diagnosis mean CAR-T is needed?
No. Many patients receive other therapies. A hematology or oncology team must compare CAR-T with other standard, investigational or supportive options for the individual case.
Does Acibadem Altunizade guarantee acceptance or product availability?
No. The responsible specialist team must confirm whether it can evaluate the case and whether an appropriate product and treatment pathway are available at the required time.
Which records are useful for preliminary review?
A current hematology summary, pathology and molecular reports, treatment history, response assessments, recent imaging or marrow results, blood counts, organ-function tests and infection information are commonly useful.
Why is close monitoring required?
CAR-T can cause serious immune, neurologic, infectious and hematologic complications. The treating center must explain monitoring, emergency response and follow-up requirements.
Can MedTransplant compare other programs?
Yes. Acibadem Altunizade is the featured partner route for this campaign, not the patient’s only option. MedTransplant can help request comparison with other suitable verified programs.
Sources and verification
Clinical responsibility
MedTransplant coordinates case preparation and referral. Hematology and oncology specialists make every diagnosis, eligibility, product, treatment, monitoring and acceptance decision.